L-AP4| CAS 23052-81-5|DC Chemicals

Cas No.:	23052-81-5
Chemical Name:	Butanoic acid,2-amino-4-phosphono-, (2S)-
Synonyms:	Butanoic acid,2-amino-4-phosphono-, (2S)-;AP4;L-(+)-2-Amino-4-phosphonobutyric acid;L-AP4;L-AP-4 L-AP4;L-AP-4
SMILES:	O=C(O)C(N)CCP(O)(O)=O
Formula:	C₄H₁₀NO₅P
M.Wt:	183.099662303925
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	L-APB is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively.
Target:	mGlu4:0.13 μM (EC50) mGlu8:0.29 μM (EC50) mGlu6:1.0 μM (EC50) mGlu7:249 μM (EC50)
In Vivo:	Paw withdrawal threshold in response to application of von Frey filaments before spinal nerve ligation is 22.6±2.4 g. The mechanical threshold decreases significantly (2.3±0.5 g, P<0.05) within 10 days after nerve ligation and remains stable for at least 8 weeks. Intrathecal injection of 5 to 30 μg of L-APB significantly increases the paw withdrawal threshold in response to application of von Frey filaments in eight nerve-ligated rats in a dose-dependent manner. The maximal effect of L-APB appears within 45 min and gradually subsided in 120 min following intrathecal administration[2].
Animal Administration:	Rats[2] The effect of L-APB (L-AP4: 5, 10, and 50 μM) on identified ascending dorsal horn neurons is studied in 20 L5 and L6 spinal nerve ligated rats. L-APB, starting with the lowest concentration, is applied topically onto the exposed spinal cord. Five to 10 min following L-APB application, the response of neurons to graded mechanical stimuli is re-examined. To ensure that the effect of L-APB on dorsal horn neurons is through group III mGluRs, the inhibitory effect of 50 μM L-APB is tested before and after topical application of 100 μM MAP4, a specific antagonist for group III mGluRs, in another 12 dorsal horn neurons. MAP4 is applied to the recording site 10 min before application of 50 μM L-APB. In addition, to determine whether topical application of L-APB affects ascending dorsal horn neurons in normal rats, the effect of 50 μM L-APB on spontaneous and evoked responses to graded mechanical stimuli is examined in 11 dorsal horn neurons from eight normal rats. Also, the effect of topical spinal application of 100 μM MAP4 alone on these cells is tested 15 to 20 min after washout of L-APB solution from the recording site[2].
References:	[1]. Selvam C, et al. Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites. J Med Chem. 2018 Mar 8;61(5):1969-1989. [2]. Chen SR, et al. Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured Rats. J Pharmacol Exp Ther. 2005 Jan;312(1):120-6.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.